yingweiwo

Doxapram (AHR-619, Dopram, Stimulex or Respiram)

Alias: AHR619; AHR-619;AHR 619; Dopram, Stimulex or Respiram.
Cat No.:V0087 Purity: ≥98%
Doxapram(AHR619, Dopram, Stimulex or Respiram) is a novel potent respiratory stimulant that acts by inhibiting the potassium channels such as TASK-1, TASK-3, TASK-1/TASK-3 with EC50 of 410 nM, 37 μM, 9 μM, respectively.
Doxapram (AHR-619, Dopram, Stimulex or Respiram)
Doxapram (AHR-619, Dopram, Stimulex or Respiram) Chemical Structure CAS No.: 309-29-5
Product category: Potassium Channel
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
5mg
25mg
50mg
100mg
250mg
500mg
Other Sizes

Other Forms of Doxapram (AHR-619, Dopram, Stimulex or Respiram):

  • Doxapram hydrochloride (AHR-619)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description

Doxapram (AHR619, Dopram, Stimulex or Respiram) is a novel potent respiratory stimulant that acts by inhibiting the potassium channels such as TASK-1, TASK-3, TASK-1/TASK-3 with EC50 of 410 nM, 37 μM, 9 μM, respectively. It is a medication used in intensive care settings to stimulate the respiratory rate in patients with respiratory failure.

Biological Activity I Assay Protocols (From Reference)
ln Vitro

In vitro activity: Doxapram is a respiratory stimulant that inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively. Doxapram preferentially stimulated the release of dopamine. It was also seen to directly inhibit Ca(2+)-independent K+ currents. Doxapram was a more potent inhibitor of the Ca(2+)-activated K+ currents recorded under control conditions. Doxapram (at 15-150 μM) also evoked 3H overflow in a concentration dependent manner, and doxapram-evoked release was inhibited by the Ca2+ channel blocker nifedipine (5 μM). The effects of doxapram on type I cells show similarities to those of the physiological stimuli of the carotid body, suggesting that doxapram may share a similar mechanism of action in stimulating the intact organ.


Kinase Assay: Doxapram inhibited TASK-1 (half-maximal effective concentration [EC50], 410 nM), TASK-3 (EC50, 37 microM), and TASK-1/TASK-3 heterodimeric channel function (EC50, 9 microM).


Cell Assay: Doxapram (1-100 microM) caused rapid, reversible and dose-dependent inhibitions of K+ currents recorded in type I cells (IC50 approximately 13 microM). doxapram was also seen to directly inhibit Ca(2+)-independent K+ currents. Doxapram was a more potent inhibitor of the Ca(2+)-activated K+ currents recorded under control conditions. Doxapram (10 microM) was without effect on L-type Ca2+ channel currents recorded under conditions where K+ channel activity was minimized and was also without significant effect on K+ currents recorded in the neuronal cell line NG-108 15, suggesting a selective effect on carotid body type I cells. The effects of doxapram on type I cells show similarities to those of the physiological stimuli of the carotid body, suggesting that doxapram may share a similar mechanism of action in stimulating the intact organ.

ln Vivo

Animal Protocol


ADME/Pharmacokinetics
Absorption, Distribution and Excretion
AFTER IV DOXAPRAM-HCL BOLUS INJECTIONS OR BRIEF INFUSIONS IN HEALTHY VOLUNTEER, PLASMA CONCN DECLINED IN MULTI-EXPONENTIAL FASHION. VOL OF DISTRIBUTION WAS 1.51 KG-1, & WHOLE BODY CLEARANCE WAS 370 ML MIN-1.
ENTERIC-COATED CAPSULES OF DOXAPRAM WERE ABSORBED RAPIDLY AFTER INITIAL DELAY, & SYSTEMIC AVAILABILITY WAS APPROX 60%. LESS THAN 5% OF AN IV DOSE WAS EXCRETED UNCHANGED IN URINE IN 24 HR.
Metabolism / Metabolites
DOXAPRAM YIELDS 4-(2-MORPHOLINOETHYL)-3,3-DIPHENYLPYRROLIDIN-2-ONE, & 1-ETHYL-4-(2-(3-OXOMORPHOLINO)ETHYL)-3,3-DIPHENYLPYRROLIDIN-2-ONE IN DOGS. PITTS, JE, BRUCE, RB, & FOREHAND, JB, XENOBIOTICA, 3, 73 (1973). /FROM TABLE/
AFTER IV DOXAPRAM-HCL BOLUS INJECTIONS OR BRIEF INFUSIONS IN HEALTHY VOLUNTEERS, A METABOLITE AHR 5955 WAS PRESENT IN PLASMA IN AMT COMPARABLE TO PARENT COMPD & HAD A SIMILAR HALF-LIFE.
Biological Half-Life
AFTER IV DOXAPRAM-HCL BOLUS INJECTIONS OR BRIEF INFUSIONS IN HEALTHY VOLUNTEER, PLASMA CONCN DECLINED IN MULTI-EXPONENTIAL FASHION. HALF-LIFE FROM 4-12 HR WAS 3.4.
References

[1]. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102(3), 779-785.

[2]. Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568(1-2): p. 116-22.

[3]. Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187(1): p. 25-8.

Additional Infomation
Doxapram is a member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering. It has a role as a central nervous system stimulant. It is a member of morpholines and a member of pyrrolidin-2-ones.
A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Doxapram is a Respiratory Stimulant. The physiologic effect of doxapram is by means of Increased Medullary Respiratory Drive.
Doxapram is a respiratory stimulant with analeptic activity. Doxapram, independent of oxygen levels, directly stimulates the peripheral carotid chemoreceptors, possibly by inhibiting the potassium channels of type I cells within the carotid body, thereby stimulating catecholamines release. This results in the prevention or reversal of both narcotic- and CNS depressant-induced respiratory depression.
A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
See also: Doxapram Hydrochloride (has salt form).
Drug Indication
For use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease.
FDA Label
Mechanism of Action
Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels.
DOXAPRAM...STIMULATE ALL LEVELS OF CEREBROSPINAL AXIS. ADEQUATE DOSES PRODUCE TONIC-CLONIC CONVULSIONS SIMILAR IN PATTERN TO THOSE PRODUCED BY PENTYLENETETRAZOL. ...ACT BY ENHANCING EXCITATION RATHER THAN BY BLOCKING CENTRAL INHIBITION.
Therapeutic Uses
Central Nervous System Stimulants; Respiratory System Agents
MEDICATION (VET): TO INCR VENTILATION & DECR SLEEPING TIME IN CATS & DOGS UNDER PENTOBARBITAL ANESTHESIA, & OCCASIONALLY IN ANESTHETIZED HORSES.
RESP CAN BE STIMULATED BY...DOSES THAT PRODUCE LITTLE GENERALIZED EXCITATION. DIRECT MEDULLARY STIMULATION IS LARGELY RESPONSIBLE FOR THIS EFFECT, BUT INDIRECT STIMULATION BY ACTIVATION OF PERIPHERAL CHEMORECEPTORS MAY... CONTRIBUTE. DURATION OF STIMULATION IS TRANSIENT AFTER SINGLE IV DOSE & SELDOM LASTS FOR...5-10 MIN.
DOXAPRAM...USED AS TEMPORARY MEASURES TO CORRECT ACUTE RESP INSUFFICIENCY IN PT WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. INTERMITTENT OR CONTINUOUS INFUSION IS NECESSARY FOR SUSTAINED RESP STIMULATION & REDUCTION IN CARBON DIOXIDE TENSION...
For more Therapeutic Uses (Complete) data for DOXAPRAM (7 total), please visit the HSDB record page.
Drug Warnings
BECAUSE OF EFFECTIVENESS OF CONTROLLED VENTILATION & STANDARD SUPPORTIVE THERAPY IN TREATMENT OF VENTILATORY FAILURE, DOXAPRAM NORMALLY SHOULD NOT BE USED TO STIMULATE VENTILATION IN PT WITH DRUG-INDUCED COMA OR AN EXACERBATION OF CHRONIC LUNG DISEASES. /HYDROCHLORIDE/
DOXAPRAM IS CONTRAINDICATED IN PT WITH CONVULSIVE DISORDERS, HYPERTENSION, CEREBRAL EDEMA, HYPERTHYROIDISM, OR PHEOCHROMOCYTOMA & IN THOSE TAKING MONOAMINE OXIDASE INHIBITORS OR ADRENERGIC AGENTS. /HYDROCHLORIDE/
Pharmacodynamics
Doxapram is an analeptic agent (a stimulant of the central nervous system). The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in respiratory rate. A pressor response may result following doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved cardiac output rather than peripheral vasoconstriction. Following doxapram administration, an increased release of catecholamines has been noted.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C24H30N2O2
Molecular Weight
378.51
Exact Mass
378.23
Elemental Analysis
C, 76.16; H, 7.99; N, 7.40; O, 8.45
CAS #
309-29-5
Related CAS #
Doxapram hydrochloride hydrate;7081-53-0
PubChem CID
3156
Appearance
White to off-white crystalline powder.
Density
1.1±0.1 g/cm3
Boiling Point
536.4±50.0 °C at 760 mmHg
Melting Point
217-219
MP: 123-124 °C /BENZOATE/
Flash Point
278.2±30.1 °C
Vapour Pressure
0.0±1.4 mmHg at 25°C
Index of Refraction
1.562
LogP
3.23
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
6
Heavy Atom Count
28
Complexity
487
Defined Atom Stereocenter Count
0
SMILES
O=C1N(CC)CC(CCN2CCOCC2)C1(C3=CC=CC=C3)C4=CC=CC=C4
InChi Key
XFDJYSQDBULQSI-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3
Chemical Name
1-ethyl-4- (2-morpholin-4-ylethyl)- 3,3-diphenyl-pyrrolidin-2-one
Synonyms
AHR619; AHR-619;AHR 619; Dopram, Stimulex or Respiram.
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: >10 mM
Water:<1 mg/mL
Ethanol:<1 mg/mL
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.6419 mL 13.2097 mL 26.4194 mL
5 mM 0.5284 mL 2.6419 mL 5.2839 mL
10 mM 0.2642 mL 1.3210 mL 2.6419 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04430790 Recruiting Drug: Doxapram Drug: Placebo Apnea of Prematurity
Respiratory Insufficiency
Erasmus Medical Center June 15, 2020 Phase 3
NCT02171910 Completed Drug: Doxapram Drug: Placebo Sedation Hypoxia Helsinki University Central Hospital October 2016 Phase 4
NCT00389909 Completed Drug: Doxapram Premature Infants Apnea Jean Michel Hascoet November 2006 Phase 4
NCT00477451 Completed Has Results Drug: Inhaled alprazolam 2 mg
Drug: IV doxapram
Treatment of Induced Panic Attack Alexza Pharmaceuticals, Inc. May 2007 Phase 2
Contact Us